Is MEDVi Legit? Our MEDVi Review

Compounded GLP-1 injections: $99 for the first month, then $199 a month at refill (checked 31 October 2026). The first-month figure sits inside a sale banner; MEDVi states that refills are locked in at the refill price. Compounded GLP-1 tablets start at $249, with no period stated on the card (checked 1 November 2026).

Branded routes are priced differently: a $99 membership plus the cost of the medication, for the Wegovy pill, the Wegovy injection and the Zepbound injection, each marked "availability is subject to change" (MEDVi's pricing page, read 18 October 2026). The $99 buys access, not treatment, and the medication is charged on top. MEDVi's main pricing page does not split its compounded prices by medication, and it does not say whether the price changes as the dose does.

MEDVi also runs a separate page for tirzepatide alone, which advertises it at $166/mo inside a sale banner (MEDVi's tirzepatide page, checked 31 October 2026). That is a sale banner price on one page: it is not the ongoing monthly price, we have not confirmed what it becomes at refill, and because MEDVi's main pricing page does not split compounded prices by medication the two cannot be compared directly. The page's "Same price, every dose" is about dose and says nothing about refills.

MEDVi states there is no membership fee or hidden fee on the compounded plans, that no insurance is required, that shipping is free and that the plans are HSA/FSA approved. Read the first-month price as an offer rather than the monthly cost: the ongoing figure is the refill price. To see how MEDVi's two figures sit against other providers over 3, 6 and 12 months, use our GLP-1 price index, which is read daily from each provider's own page.

Tirzepatide prices across US providers: Cheapest tirzepatide online, checked daily

• Names three partner compounding pharmacies: Triad Rx, Red Rock Home Pharmacy and Beaker Pharmacy
• Names the prescriber network, OpenLoop Health, with treatment provided by CareGLP Affiliated P.C.s
• Compounded GLP-1 injections $99 for the first month, $199 at refill (checked 31 October 2026); tablets from $249 (checked 1 November 2026)
• Publishes a full cancellation and refund policy, including a 72-hour cooling-off window
• Free dietician visits and care coaching included, subject to eligibility
• HSA/FSA approved; no insurance required

Compounded GLP-1 injections and tablets, plus branded GLP-1 routes sold as a membership plus medication cost. Prescriptions are issued only after an online consultation with an independent licensed provider. MEDVi states that compounded medications are dispensed by state-licensed pharmacies but are not FDA approved, and that although the facilities are FDA-regulated the medicines are not FDA-approved or evaluated for safety, efficacy or quality.

Online assessment, then a consultation with an OpenLoop Health clinician after checkout, who determines eligibility and retains the prescribing decision. MEDVi states the assessment itself does not create a doctor-patient relationship.

Free, expedited shipping is included on the compounded plans.

MEDVi is a US online weight-loss service. You complete an online intake, a clinician from OpenLoop Health or the CareGLP Affiliated P.C.s decides whether to prescribe, and a partner compounding pharmacy (MEDVi names Triad Rx, Red Rock Home Pharmacy and Beaker Pharmacy) ships the medication to your home. MEDVi states that it is not a pharmacy and does not make the prescribing decision itself (MEDVi's own pages, read 18 October 2026).

Its core product is compounded GLP-1 medication, as a weekly injection or a daily dissolvable tablet, sold on a subscription that includes the clinician visit, messaging support and shipping. Compounded medicines are not FDA-approved. MEDVi also sells branded GLP-1 plans as a membership plus the cost of the medication, and markets a separate QUAD product, covered further down this page.

Two things to know before reading MEDVi reviews: the FDA sent MEDVi a warning letter in February 2026 over how it labelled and marketed its compounded products, and its public ratings split sharply between Trustpilot and the BBB. Both are set out in the next two sections.

MEDVi is a real, operating US telehealth company. It publishes a postal address (131 Continental Dr., Ste 305, Newark, Delaware), names the pharmacies that dispense its compounded medicines, names the prescriber network behind them (OpenLoop Health), and publishes a cancellation and refund policy (MEDVi's own pages, read 18 October 2026). The FDA's warning letter is addressed to MEDVi, LLC dba MEDVi at the same Newark address.

Legitimate does not mean uncomplicated. In February 2026 the FDA issued warning letter 721455 over how MEDVi labelled and marketed its compounded GLP-1 products; the FDA notice further down this page sets out what the letter says, and the FDA's page showed no sign of closure on 18 October 2026. Public ratings point in different directions: Trustpilot shows 4.3 from 15,102 reviews (read 26 October 2026), while the BBB shows an F rating and 782 complaints over three years (read 22 October 2026). The evidence check below gives both with their dates.

What we could not verify: LegitScript status (MEDVi links the checker, but its result sits behind a human-verification step), which pharmacy fills a given order, and any reply MEDVi has made to the FDA. None of this is a statement about whether treatment is right for you, which is a question for a clinician.

MEDVi publishes two compounded routes and three branded ones. Compounded GLP-1 injections are $99 for the first month, an introductory price, and $199 for refills (checked 31 October 2026). Compounded GLP-1 tablets start at $249 (checked 1 November 2026), and the branded options are sold as a $99 membership plus the cost of the medication itself (checked 1 November 2026). That last structure matters when comparing: the $99 is not the price of treatment, it is the price of access, and the medication is charged on top at whatever it costs.

On the compounded plans MEDVi states there is no membership fee and no hidden fee, that no insurance is required, that shipping is free and expedited, and that the plans are HSA/FSA approved. Included in the price it lists the prescription, one-to-one physician guidance, 24/7 support, and free dietician visits and care coaching, though that last item carries an asterisk, qualified as "free to end users subject to insurance and copays eligibility to be determined at time of visit". Read it as conditional rather than bundled.

What you pay after the first month is worth resolving at intake. MEDVi's own FAQ says the programme starts at $99 for the first month and that refills are locked in at $199, so the $99 is an introductory price, not the ongoing one (checked 31 October 2026). Ask whether the sale price carries into a second month and what the refill price covers.

MEDVi names three partner compounding pharmacies on its homepage: Triad Rx, Red Rock Home Pharmacy (linked to redrockhomepharmacy.com, which calls itself Red Rock Compounding Pharmacy) and Beaker Pharmacy and Compounding. It states that it is not acting as a pharmacy and does not produce compounded medications. It does not say which of the three fills a given order, so the honest answer for your order is one of the three, and you should ask which at intake.

FDA record for Triad Rx. On 5 February 2019 the FDA issued warning letter 569659 to Triad Rx, Inc. of Daphne, Alabama, citing serious deficiencies in its practices for producing sterile drug products and products prepared under insanitary conditions (11 numbered observations); the letter also said compounded products made with GHRP-2, GHRP-6 and chromium picolinate were not eligible for the section 503A exemptions. On 3 May 2023 the FDA issued a close-out letter stating that it appears Triad Rx adequately addressed the violations and acknowledging that the firm no longer produces sterile drug products; it also says it does not preclude future regulatory action. The same pharmacy is named on our Embody review. Most of the compounded GLP-1 injections MEDVi sells are sterile products, and we do not know whether Triad Rx fills any MEDVi order.

The FDA's compounding-actions page (current as of 5 October 2026, read as text on 18 October 2026) lists Triad Rx as a 503A facility and shows no entry under the Red Rock or Beaker names MEDVi uses. Absence from that list is not proof of a clean record, and the FDA's own search tool is unreliable for names, so treat it as "none found".

Sources: FDA warning letter 569659 (checked 18 October 2026); FDA close-out letter, 3 May 2023 (checked 18 October 2026); FDA compounding: inspections, recalls and other actions (checked 18 October 2026).

Most telehealth platforms in this segment say "a state-licensed compounding pharmacy" and stop. MEDVi names three: Triad Rx, Red Rock Home Pharmacy, and Beaker Pharmacy's compounding arm, each linked from its own site. It does not say which one fills a given order, but a named pharmacy can be looked up with a state board of pharmacy, and an unnamed one cannot. That is a real difference in what a buyer is able to check.

Prescribing is equally explicit. MEDVi states that OpenLoop Health, a network of US-licensed doctors, applies exclusionary criteria to the intake assessment, that an OpenLoop clinician meets the patient after checkout to determine eligibility, and that "OpenLoop Health clinicians retain the decision to prescribe compounded GLP-1s". Medical treatment is provided by CareGLP Affiliated P.C.s together with OpenLoop Health. MEDVi is candid that its own assessment "does not create a doctor-patient relationship". The relationship is with the clinician network, not with the brand.

On regulatory status MEDVi's wording is among the clearer ones in the segment: compounded medications "are dispensed by state-licensed pharmacies but are not FDA approved", and more fully, that compounded GLP-1s "are produced in FDA-regulated facilities. Although these facilities are highly regulated, the medications are not FDA-approved or evaluated for safety, efficacy, or quality." The distinction between a regulated facility and a reviewed medicine is one most marketing blurs, and MEDVi draws it.

MEDVi runs a second, separate line under the QUAD name at quad.medvi.org, linked from the men's-health section of its own homepage. It describes MEDVi QUAD™ as "the world's first 4-in-1 formula", a rapid-absorb liquid taken under the tongue, combining four ingredients it names openly: apomorphine, L-citrulline, sildenafil and tadalafil. It is priced at $114 a month, shown as a "starting at" figure against a struck-through $179 and labelled "36% off retail", with the doctor consultation, rush shipping and 24/7 medical support included and cancellation stated as available at any time (checked 18 September 2026).

The prescribing route is the one MEDVi describes for its weight-loss line. You complete an online intake, which MEDVi says takes three minutes; a US-licensed doctor reviews it, which MEDVi says happens within 24 hours; and if approved, MEDVi states the prescription is issued immediately and shipped in a plain, unmarked package. MEDVi states that if you do not qualify you are not charged. As on its GLP-1 pages, MEDVi states it "does not produce compounded medications" and is "partnered with multiple USA certified pharmacies", but the three pharmacies it names on its homepage are not repeated on the QUAD site, and the QUAD pages do not say which pharmacy fills an order, whether the product is compounded or dispensed as branded generics, which states it is available in, or what dose of each ingredient it contains.

Two gaps are worth knowing before you compare QUAD with the weight-loss plans. MEDVi's homepage contradicts itself: the men's-health section links three times to the live QUAD store and also carries a button labelled "Coming Soon" pointing at that same store. And the QUAD footer links to a different refund policy from the one the homepage links to: medvi.org/refund-policy.html, which contains no 72-hour cooling-off refund at all and states that, other than medical disqualification, "IN NO EVENT SHALL YOU BE ISSUED A REFUND UPON CANCELLATION OF THE SUBSCRIPTION SERVICES". Ask at intake which of the two governs a QUAD subscription, and get the answer in writing. MEDVi publishes no clinical data for the four-ingredient combination, and nothing here is a statement about whether it works.

Ro and MEDVi sell different things at the centre. Ro sells brand-name, FDA-approved medicines (the Wegovy pill and pen, Zepbound and Ozempic, as set out in our Ro review last updated 29 September 2026). MEDVi's main plans are compounded GLP-1 injections and tablets, which are not FDA-approved, with branded Wegovy and Zepbound available through a membership route.

On price, the closest like-for-like is MEDVi's branded route: a $99 membership plus the medication, against Ro's membership ($39 for the first month, then $74 to $149 a month by plan) plus the medication as a separate charge. MEDVi's compounded plans have no membership at all and are a different product. Ro says its insurance concierge pursues coverage for eligible patients; MEDVi says no insurance is required on its compounded plans and that they are HSA/FSA approved.

On refunds, Ro states that its $39 is refunded if you are not eligible for GLP-1s. MEDVi gives a full refund on medical disqualification and a full refund if you cancel within 72 hours of starting before any service, and none for the month of cancellation on a monthly plan. For the two side by side on price, prescriber model and cancellation terms, see our full Ro vs MEDVi comparison.

MEDVi and Embody are the closest pair here. Both sell compounded GLP-1 injections online, both say they are not pharmacies, both use clinicians in the OpenLoop Health network, and both name Triad Rx and a pharmacy called Red Rock among their partners. MEDVi lists an introductory $99 first month and $199 refills (checked 31 October 2026); Embody advertises $49 for semaglutide and $99 for tirzepatide, flat per medication (checked 31 October 2026).

Both take payment before a clinician decides whether you qualify, and both set a cancellation notice of 72 hours before the next billing date. The refund terms differ: MEDVi adds a full refund for cancelling within 72 hours of starting before any service, while Embody states no cooling-off period and refunds only the unused part of the term, less services already provided, on medical disqualification (Embody's Refund Policy, updated 25 August 2026).

The two have different public records, and neither is a clinical assessment. MEDVi's Trustpilot, BBB and FDA record is set out under "MEDVi reviews, complaints and refunds" and "MEDVi evidence check" on this page, with the Embody figures beside it in the evidence check. Our full Embody vs MEDVi comparison sets the two side by side.

MEDVi and Trim Rx open at the same number for compounded GLP-1, $99 (MEDVi's is a first-month price, with refills at $199), which makes the non-price differences the whole comparison. MEDVi names its pharmacies, names its prescriber network and publishes refund terms; TrimRx names no pharmacy and publishes no refund terms. TrimRx, in exchange, states that its price does not move as the dose changes, which MEDVi does not say either way. One is more transparent about the chain; the other is more explicit about what happens to the bill.

Against Trimi, the difference is how commitment is priced. Trimi's $99 and $125 monthly equivalents require a twelve-month plan paid upfront ($1,188 or $1,500); its month-to-month rates are $175 and $235. MEDVi's introductory $99 asks for no year in advance, though refills are $199. Trimi also offers a six-month money-back promise that MEDVi does not match, but Trimi's order becomes final the moment a prescription is issued, where MEDVi's 72-hour window runs from the start of the term.

Against Willow at $299 a month, MEDVi is cheaper at entry ($99 for the first month, though refills are $199), though Willow publishes four named treatment routes against MEDVi's two compounded ones. Across all four, what cannot be compared is effectiveness: each publishes its own outcome figures and each qualifies them in its own small print, MEDVi's noting that its claims are self-reported and that results shown are "not typical".

ElixaMD, which shares MEDVi's Newark address, its three partner pharmacies, its clinician wording and its first month and refill price structure, is reviewed here; we could not confirm who operates it.

Other side-by-side comparisons: Wellmedr vs MEDVi · Eden Health vs MEDVi · Fridays Health vs MEDVi · TrimRx vs MEDVi · Hims vs MEDVi · Shed vs MEDVi

Which pharmacy will fill my order? MEDVi names three partner pharmacies but does not say which one fills a given order. Ask, so you can look that pharmacy up with its state board of pharmacy.

Is $99 the ongoing price, and what will I pay at refill? MEDVi shows $99 inside a seasonal sale banner and in its FAQ as the price for the first month, and states that refills are locked in at $199 (checked 31 October 2026).

Does my price change as my dose goes up? MEDVi does not say either way.

Which refund policy covers my plan, and when exactly must I cancel? MEDVi's homepage and its QUAD site link to two different refund policies, and a cancellation has to reach support at least 72 hours before the next billing date or that cycle is charged. Get the answer in writing.

Are the dietician visits and care coaching actually free for me? MEDVi lists them as included but qualifies them as "subject to insurance and copays eligibility".

Has MEDVi responded to FDA warning letter 721455, and has the labelling it covered been changed? MEDVi's response is not published on the FDA page.

Trustpilot shows MEDVi at 4.3 from 15,102 reviews, and shows MEDVi replying to 99% of negative reviews (Trustpilot's own figures, read 26 October 2026); when we read it on 22 October 2026, 79% of the reviews were five-star and 12% one-star. The BBB profile shows an F rating, 782 complaints in the last three years (666 of them in the last 12 months) and 632 customer reviews, and gives failure to respond to 145 complaints as a reason for the rating (read 22 October 2026; on 18 October it also showed no BBB accreditation). The two are different samples and cannot be averaged: a score from many reviews and a count of formal complaints measure different things.

Themes in the reviews: among the Trustpilot reviews visible on 18 October 2026, the recurring themes were billing (charges that differ from what was expected, or that continued after cancelling), difficulty getting a refund, delayed deliveries, dosage or prescription errors, and trouble cancelling or reaching the company. These are customers' accounts, not findings, and we have not audited individual reviews.

The refund policy is set out in full under "MEDVi cancellation and refunds, explained" below. In short: a full refund if you cancel within 72 hours of starting before receiving any service, or if a clinician disqualifies you on medical grounds; no refund for the month in which you cancel on a monthly plan; and notice of at least 72 hours before the next billing date to stop the next charge. MEDVi's QUAD site links a stricter refund policy than its homepage does.

A competing provider's review (Ivy Rx, read 18 October 2026) reports reviewers describing charges after cancelling, a refused refund and prices that rose at renewal. Ivy Rx sells a competing service, these are its summaries of other people's reports, and we have not verified them.

Sources: MEDVi on Trustpilot (checked 22 October 2026); MEDVi BBB profile (checked 22 October 2026).

MEDVi publishes a cancellation and refund policy (MEDVi's own pages, read 18 October 2026). You may cancel at any time, but the request must reach patient support at least 72 hours before the next billing date; inside that window the next cycle is charged and cancellation takes effect the cycle after. Service continues to the end of the paid cycle.

Refunds are more limited than cancellation. If you cancel within the first 72 hours of the subscription term and have received no services, you get a full refund. If a clinician disqualifies you on medical grounds, you get a full refund. MEDVi states this twice, including for the consultation. Otherwise, on a monthly plan, MEDVi's policy states in capitals that no refund is issued for the month in which cancellation occurs or for any prior month. On plans billed two or more months at a time, months for which no medication shipped are refunded.

As MEDVi's policy notes, federal rules generally prohibit returning prescription medication to a pharmacy for refund or reuse once it has been dispensed for a patient, which is why refunds on shipped medicine are limited. Damaged or incorrect items are handled separately and replaced by the pharmacy on evidence.

Every MEDVi figure below was read on 18 October 2026, unless another date is given, from the source linked at the foot of this section. It records what third parties publish about MEDVi, not whether treatment is right for you.

Trustpilot (read 26 October 2026): TrustScore 4.3 from 15,102 reviews; Trustpilot shows MEDVi replying to 99% of negative reviews. On 22 October 2026, 79% of the reviews were five-star and 12% one-star. BBB: F rating, not accredited, 770 complaints in three years and 660 in the last 12 months, 628 customer reviews, no star average shown. Re-read on 22 October 2026: BBB F, 782 complaints in three years, 666 in the last 12 months, 632 customer reviews.

FDA: warning letter 721455 to MEDVi, LLC dba MEDVi, dated 20 February 2026 (the FDA page is current as of 3 March 2026 and shows no close-out). It alleges misbranding because pictured products carry MEDVi on the label, which the FDA says suggests MEDVi is the compounder, and false or misleading "same active ingredient" claims. It does not allege adverse events, contamination or a recall. For the pharmacies, see "Which pharmacy fills MEDVi prescriptions?" above.

For comparison with Embody (read 30 October 2026, from our Embody review): Trustpilot 3.9 from 11,117 reviews; a BBB C+ rating for its operating company with 294 complaints; no FDA warning letter found for Embody itself, though one of its named pharmacies has an FDA record. These are third-party records, not a clinical assessment of either provider.

LegitScript: MEDVi links the checker, but we could not retrieve a result, so we make no statement about it.

Search results for "MEDVi reviews" are dominated by Reddit threads, Trustpilot and Facebook groups. We link none of the user threads: they are individual accounts we cannot verify, and the themes in them match what Trustpilot and the BBB show.

Sources: MEDVi on Trustpilot (checked 18 October 2026); MEDVi BBB profile (checked 18 October 2026); FDA warning letter 721455 (checked 18 October 2026).

Lawsuits. Court records show MEDVi, LLC as a defendant in three federal cases, all in the US District Court for the Central District of California. Kymberly Starling v. Medvi LLC et al (2:25-cv-11282) was filed on 24 November 2025 under the Telephone Consumer Protection Act over marketing text messages; MEDVi filed an answer on 9 February 2026, the plaintiff filed a notice of settlement on 8 April 2026 and the case was dismissed with prejudice on 6 May 2026 (UniCourt docket, read 28 October 2026). Dallas James et al v. Medvi LLC (8:26-cv-00641) was filed on 20 March 2026 as a class action under California Business and Professions Code section 17529.5, the state anti-spam law; the complaint alleges that affiliate marketers sent emails with falsified headers and subject lines routing readers to MEDVi, seeks $1,000 per email, and pleads a class of at least 100,000 people (Law360 case header; Drug Discovery and Development, 4 April 2026). The New York Times described that case as pending in an editor's note added around 10 April 2026; we could read no later docket entry. A third class action, E.P. et al v. Medvi, LLC (2:26-cv-03796), was docketed on 9 April 2026 (Law360 case header); the complaint was not available to us and its claims are not described here. An earlier TCPA case in the Southern District of Florida, Siuksta v. MEDVi, LLC (1:25-cv-22185, 2025), was voluntarily dismissed, according to Drug Discovery and Development. None of these is a finding against MEDVi: one settled, one was withdrawn, and two were open on the last date we could read.

A lawsuit often listed next to MEDVi's name is one it is not a party to. A November 2025 complaint in the US District Court for the District of Delaware names OpenLoop Health and the compounding pharmacy Triad Rx, not MEDVi, and alleges that compounded oral tirzepatide tablets, which the plaintiff says were bought through MEDVi, are not absorbed (Drug Discovery and Development, 4 April 2026). Compounded GLP-1 medicines are not FDA approved, and we make no statement about whether any product works.

Data breach. There is no breach of MEDVi's own systems on the public record. The breach attached to MEDVi in search results is at OpenLoop Health, Inc. of Des Moines, Iowa, which MEDVi names on its own pages as its prescriber network. OpenLoop's notification letter, filed with the Montana Department of Justice and dated 17 March 2026, states that on 7 January 2026 it learned an unauthorised third party had accessed its systems and removed information, that the access ran from 7 to 8 January 2026, and that the incident did not involve electronic health records, Social Security numbers or financial account information; it offers a year of identity monitoring. Letters filed with the California and Texas attorneys general list names, addresses, email addresses, dates of birth and medical information as the data involved; the Texas Attorney General listing of 18 March 2026 gives 68,160 Texas residents, and the US Department of Health and Human Services breach portal lists 716,000 individuals (HIPAA Journal, 11 May 2026; SecurityWeek). A threat actor claimed 1.6 million patients; OpenLoop has not confirmed that figure (Iowa Capital Dispatch, 19 February 2026). A class action over the breach was filed against OpenLoop in the Southern District of Iowa; MEDVi is not a party. OpenLoop's letter does not name the companies whose patients were affected, no notice issued in MEDVi's name was found, and neither company has stated whether MEDVi customers' data was included. If you were a MEDVi patient before January 2026 and want to know, ask MEDVi and OpenLoop directly.

The $1.8 billion story. On 2 April 2026 the New York Times published a profile of MEDVi and its founder, Matthew Gallagher, presenting it as a two-person company built with AI tools and on track for $1.8 billion in sales in 2026. The figure is projected revenue, not a valuation; the company has raised no outside funding and has no official valuation, and 2025 sales were reported as $401 million (Moneywise, 7 April 2026; Techdirt quoting the Times). Around 10 April 2026 the Times added an editor's note saying the piece should have included the FDA warning letter and the pending California anti-spam class action (Futurism, 10 April 2026). The story is about the company's marketing and revenue; it says nothing about the medicines, which are the compounded GLP-1 products described elsewhere on this page.

What MEDVi has said. In a statement reported by Futurism on 9 April 2026, Mr Gallagher said "My company MEDVi has never received a letter from the FDA", that the letter named the domain medvi.io rather than medvi.org and was "directed at an affiliate marketing agency", that MEDVi had "only recently become aware of what appear to be advertisements featuring potentially AI-generated medical practitioners", and that it had "immediately reached out to the affiliate and required them to remove the materials". The FDA's letter is addressed to MEDVi, LLC dba MEDVi at 131 Continental Dr., Newark, Delaware, the postal address MEDVi publishes, and the FDA page showed no close-out on 18 October 2026. In the Starling case MEDVi filed an answer and then settled. We found no public statement from MEDVi on the James or E.P. cases or on the OpenLoop breach.

What we could not verify, and have left out: the contents of the E.P. complaint, any state-court case, any figure for how many MEDVi customers were in the OpenLoop breach, and the outcome of the James case after April 2026. Court docket sites refused automated reads on 28 October 2026, so the docket facts above come from UniCourt and Law360 case headers rather than PACER itself.

Sources: Starling v. Medvi LLC docket (UniCourt) (checked 28 October 2026); James v. Medvi LLC, 8:26-cv-00641 (Law360) (checked 28 October 2026); E.P. v. Medvi, LLC, 2:26-cv-03796 (Law360) (checked 28 October 2026); Drug Discovery and Development, 4 April 2026 (checked 28 October 2026); OpenLoop Health notification letter, Montana Department of Justice (checked 28 October 2026); HIPAA Journal on the OpenLoop breach, 11 May 2026 (checked 28 October 2026); SecurityWeek on the OpenLoop breach (checked 28 October 2026); Iowa Capital Dispatch, 19 February 2026 (checked 28 October 2026); Moneywise via AOL, 7 April 2026 (checked 28 October 2026); Futurism, MEDVi statement, 9 April 2026 (checked 28 October 2026); Futurism, New York Times editor's note, 10 April 2026 (checked 28 October 2026).

PCF reviews online programs for comparison purposes only. Provider details, pricing, availability, and medication paths can change. Confirm current terms directly and consult a licensed clinician before making medical decisions.

Sources for this review, each read on the date shown:

• The Trustpilot score, review count, star split and complaint themes: MEDVi on Trustpilot, checked 18 October 2026.
• The BBB rating, accreditation status, complaint counts and review count: MEDVi BBB profile, checked 18 October 2026.
• MEDVi's warning letter and the absence of a close-out: FDA warning letter 721455, checked 18 October 2026.
• Triad Rx warning letter 569659, issued 5 February 2019: FDA warning letter 569659 to Triad Rx, Inc., checked 18 October 2026.
• The FDA close-out of warning letter 569659, 3 May 2023: FDA close-out letter for warning letter 569659, checked 18 October 2026.
• The Triad Rx 503A entry and the absence of entries under the Red Rock and Beaker names: FDA compounding: inspections, recalls and other actions, checked 18 October 2026.
• The branded-route pricing structure, the three named pharmacies and the prescriber wording: MEDVi pricing page and homepage, checked 18 October 2026.
• The cancellation and refund terms: MEDVi cancellation and refund policy, checked 18 October 2026.
• A competitor's summary of complaints, attributed and not verified: Ivy Rx: MEDVi weight loss reviews, checked 18 October 2026.
• Starling v. Medvi LLC (2:25-cv-11282): filing, answer, settlement and dismissal dates: UniCourt docket, Starling v. Medvi LLC, checked 28 October 2026.
• James v. Medvi LLC (8:26-cv-00641): court, judge and class-action status: Law360 case header, James v. Medvi LLC, checked 28 October 2026.
• E.P. v. Medvi, LLC (2:26-cv-03796): court, judge and docket date: Law360 case header, E.P. v. Medvi, LLC, checked 28 October 2026.
• The OpenLoop Health breach dates and the data the letter excludes: OpenLoop Health notification letter, Montana Department of Justice, checked 28 October 2026.
• The OpenLoop breach data types, the Texas and HHS figures: HIPAA Journal, OpenLoop Health data breach, checked 28 October 2026.
• MEDVi's April 2026 statement and the New York Times editor's note: Futurism, 9 and 10 April 2026, checked 28 October 2026.